U.S. stocks edge higher; solid earnings season continues
Masimo Corporation (NASDAQ:{{16565|MAMASI), a global medical technology company with a market capitalization of $10.28 billion, has reached a new 52-week high, with its stock price soaring to $191.92. According to InvestingPro analysis, the stock is currently trading above its Fair Value, suggesting careful consideration for new positions. This milestone reflects a significant uptrend in the company’s market performance, marking a robust 48% increase in its stock value over the past year, with an impressive 63% surge in just the past six months. Investors have shown growing confidence in Masimo’s innovative product line and strong financial health, bolstered by seven analysts revising their earnings expectations upward, with price targets ranging from $155 to $215. The 52-week high serves as a testament to Masimo’s strategic initiatives and its commitment to delivering shareholder value amidst a dynamic market landscape. For deeper insights into Masimo’s valuation and growth prospects, access the comprehensive Pro Research Report available exclusively on InvestingPro.
In other recent news, Masimo Corporation reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of $1.80, compared to the forecast of $1.42. The company also exceeded revenue projections, reporting $600.7 million against an anticipated $591.64 million. Following these results, BTIG analyst Sean Lavin raised the price target for Masimo shares to $206 from $178, maintaining a Buy rating on the stock. Masimo has updated its 2025 guidance, projecting healthcare revenue between $1.50 billion and $1.53 billion, reflecting an 8-11% year-over-year increase. The company has also raised its adjusted EPS guidance for 2025 to $5.10-$5.40, surpassing the consensus estimate of $4.69. Masimo’s operating profit grew by 46% in the fourth quarter, with operating margins improving by 570 basis points to 22.4%. The company has experienced a record year in new contracts, amounting to $432 million, contributing to its market share gains. CEO Katie Szyman emphasized Masimo’s focus on reinforcing its leadership in the healthcare market and devising a long-term growth strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.